FDA approves MAVYRET for acute hepatitis C in 8-week treatment

The FDA has approved Enanta Pharmaceuticals' MAVYRET as an eight-week treatment for acute hepatitis C, based on Phase 3 trial data showing a 96% cure rate; this expands MAVYRET's indication to include both acute and chronic HCV in adults and children over three. Enanta, with a $173 million market cap and a 32% year-to-date return, is also advancing its immunology pipeline, leading analysts at JMP and Citizens JMP to raise their price targets to $23 and $24 respectively, despite concerns about rapid cash burn. The company's cash reserves are expected to fund operations into fiscal year 2028.

Analysis

Enanta Pharmaceuticals (NASDAQ:ENTA) has secured a significant regulatory win with the U.S. Food and Drug Administration's approval for an expanded indication of MAVYRET, now the only eight-week treatment for acute hepatitis C virus (HCV) infection. This development, supported by Phase 3 trial data showing a 96% cure rate, broadens MAVYRET's application to include both acute and chronic HCV in adults and pediatric patients three years and older, without cirrhosis or with compensated cirrhosis. The company, currently valued at a $173 million market cap, has demonstrated strong market performance with a 32% year-to-date return. Despite a robust current ratio of 5.29 and cash reserves of $193 million—expected to fund operations into fiscal year 2028 following a $33.8 million tax refund—InvestingPro data indicates a rapid cash burn associated with its ongoing development efforts. The FDA's prior granting of Breakthrough Therapy Designation for MAVYRET in acute HCV highlights its therapeutic advancement. Glecaprevir, one of MAVYRET’s active ingredients, was discovered by Enanta and is commercialized by AbbVie. Analyst sentiment has turned more positive, evidenced by JMP and Citizens JMP raising their price targets to $23 and $24, respectively, referencing the MAVYRET approval and Enanta's strategic focus on its immunology pipeline. This pipeline includes zelicapavir for pediatric RSV, with Phase 2 data expected in 2025, an adult RSV program with Phase 2 results anticipated in Q3 2025, and ongoing development of oral KIT and STAT6 inhibitors, with a third immunology program slated for announcement later this year.

Key Decisions for Investors

• Investors should consider the enhanced revenue potential from MAVYRET's expanded FDA approval and the positive sentiment reflected in recent analyst price target upgrades to $23 and $24.
• Closely monitor Enanta's cash burn rate in upcoming quarterly reports, despite stated reserves lasting into fiscal year 2028, especially in light of its ambitious immunology pipeline development.
• Key catalysts to watch include Phase 2 clinical trial results for its RSV programs, with adult data expected in Q3 2025 and pediatric data in 2025, alongside the unveiling of a new immunology program later in the current year, which could significantly influence the stock's trajectory.